Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) went up by 5.23% from its latest closing price compared to the recent 1-year high of $20.50. The company’s stock price has collected 19.33% of gains in the last five trading sessions. Press Release reported on 09/10/21 that Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23(rd) Annual Global Investment Conference
Is It Worth Investing in Aurinia Pharmaceuticals Inc. (NASDAQ :AUPH) Right Now?
Plus, the 36-month beta value for AUPH is at 0.52. Opinions of the stock are interesting as 8 analysts out of 9 who provided ratings for Aurinia Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $28.33, which is -$9.43 below the current price. AUPH currently public float of 117.64M and currently shorts hold a 14.83% ratio of that float. Today, the average trading volume of AUPH was 3.74M shares.
AUPH’s Market Performance
AUPH stocks went up by 19.33% for the week, with a monthly jump of 37.16% and a quarterly performance of 65.59%, while its annual performance rate touched 44.25%. The volatility ratio for the week stands at 8.04% while the volatility levels for the past 30 days are set at 7.87% for Aurinia Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 28.29% for AUPH stocks with a simple moving average of 51.29% for the last 200 days.
Analysts’ Opinion of AUPH
Many brokerage firms have already submitted their reports for AUPH stocks, with H.C. Wainwright repeating the rating for AUPH by listing it as a “Buy.” The predicted price for AUPH in the upcoming period, according to H.C. Wainwright is $35 based on the research report published on January 25th of the current year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AUPH reach a price target of $28, previously predicting the price at $34. The rating they have provided for AUPH stocks is “Buy” according to the report published on November 03rd, 2020.
BTIG Research gave a rating of “Buy” to AUPH, setting the target price at $20 in the report published on June 17th of the previous year.
AUPH Trading at 47.93% from the 50-Day Moving Average
After a stumble in the market that brought AUPH to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 2.10% of gains for the given period.
Volatility was left at 7.87%, however, over the last 30 days, the volatility rate increased by 8.04%, as shares surge +37.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +61.37% upper at present.
During the last 5 trading sessions, AUPH rose by +19.33%, which changed the moving average for the period of 200-days by +52.77% in comparison to the 20-day moving average, which settled at $16.60. In addition, Aurinia Pharmaceuticals Inc. saw 51.34% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at AUPH starting from Martin Michael Robert, who sale 7,500 shares at the price of $18.10 back on Sep 07. After this action, Martin Michael Robert now owns 176,861 shares of Aurinia Pharmaceuticals Inc., valued at $135,750 using the latest closing price.
Huizinga Robert Bindert, the EVP of Research of Aurinia Pharmaceuticals Inc., sale 5,000 shares at $18.30 during a trade that took place back on Sep 07, which means that Huizinga Robert Bindert is holding 138,592 shares at $91,500 based on the most recent closing price.
Stock Fundamentals for AUPH
Current profitability levels for the company are sitting at:
- -194.50 for the present operating margin
The net margin for Aurinia Pharmaceuticals Inc. stands at -204.88. The total capital return value is set at -28.27, while invested capital returns managed to touch -29.81.
Based on Aurinia Pharmaceuticals Inc. (AUPH), the company’s capital structure generated 2.06 points at debt to equity in total, while total debt to capital is 2.02. Total debt to assets is 1.81, with long-term debt to equity ratio resting at 1.87. Finally, the long-term debt to capital ratio is 1.83.
The receivables turnover for the company is 72.32 and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.11.